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Abstract
The chromatin remodelling protein ATRX is associated with the rare genetic disorder ATR-X syndrome. This
syndrome includes developmental delay, cognitive impairment, and a variety of skeletal deformities. ATRX plays a
role in several basic chromatin-mediated cellular events including DNA replication, telomere stability, gene
transcription, and chromosome congression and cohesion during cell division. We have used a loss-of-function
approach to directly investigate the role of Atrx in the adult skeleton in three different models of selective Atrx loss.
We specifically targeted deletion of Atrx to the forelimb mesenchyme, to cartilage and to bone-forming osteoblasts.
We previously demonstrated that loss of ATRX in forelimb mesenchyme causes brachydactyly while deletion in
chondrocytes had minimal effects during development. We now show that targeted deletion of Atrx in osteoblasts
causes minor dwarfism but does not recapitulate most of the skeletal phenotypes seen in ATR-X syndrome patients.
In adult mice from all three models, we find that joints lacking Atrx are not more susceptible to osteoarthritis, as
determined by OARSI scoring and immunohistochemistry. These results indicate that while ATRX plays limited roles
during early stages of skeletal development, deficiency of the protein in adult tissues does not confer susceptibility to
osteoarthritis.
Citation: Solomon LA, Russell BA, Makar D, Bérubé NG, Beier F (2013) Loss of ATRX Does Not Confer Susceptibility to Osteoarthritis. PLoS ONE 8(12):
e85526. doi:10.1371/journal.pone.0085526
Editor: Valérie Geoffroy, INSERM U606 - university Paris 7, France
Received September 16, 2013; Accepted November 27, 2013; Published December 30, 2013
Copyright: © 2013 Solomon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an operating grant from the Canadian Institutes for Health Research to N.G.B. and F.B. [MOP102539](http://
www.cihr-irsc.gc.ca), and an Ontario Graduate Studentship (OGS) (https://osap.gov.on.ca/OSAPPortal/en/A-ZListofAid/PRD19842319.html) to L.A.S. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: nberube@uwo.ca (NGB); fbeier@uwo.ca (FB)

Introduction

histone acetylases and deacetylases have also been
associated with arthritis[7]. The aging-related gene SirT1 is of
particular interest, as it codes for a protein capable of
deacetylating histones and other proteins[8]. Expression of
SirT1 in chondrocytes is associated with increased survival and
down-regulation of the proapoptotic protein PTP1B associated
with OA[9]. Age-related diseases, as well as normal aging, are
frequently influenced by changes in chromatin structure,
leading to deleterious effects on cell and tissue function[10].
Hypomorphic mutations causing dysfunction of the ATRX
chromatin remodeling protein can lead to various skeletal
deformities, including dwarfism, spine deformities and
malformation of the hands and feet[11,12]. These defects occur
in conjunction with developmental delay, psychomotor and
mental retardation, distinct facial features, urogenital
abnormalities and α-thalassemia[11]. Radiological analysis in a
few cases has shown that individuals with ATRX mutations
show delayed bone age[11]. ATRX contains two conserved
domains where the majority of disease-related mutations are

Osteoarthritis (OA) is a degenerative joint disease to which
there is no cure. It is characterized by the degeneration of
articular cartilage and changes in other joint tissues including
subchondral bone and synovium. Cartilage is maintained by a
balance of both anabolic and catabolic activities. OA occurs
when these processes are in disequilibrium and catabolism
outweighs anabolic repair[1]. Osteoarthritis can be triggered by
many factors including diet, injury, strain and genetic
abnormalities[1–5]. However, the molecular mechanisms
driving disease onset and progression are incompletely
understood.
Alterations in epigenetic mechanisms affecting gene
expression have been previously reported in articular
chondrocytes[4]. A recent study has linked genetic variants of
DOT1L, an evolutionarily conserved histone methyltransferase
required for chondrogenic differentiation, to increased
susceptibility to osteoarthritis[6]. Alterations in expression of
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located. The N-terminus contains a plant homeodomain-type
(PHD-type) zinc finger that acts as a histone reader module by
mediating binding to specific post-translational modifications on
histone H3[13–15]. Towards the C-terminus, ATRX contains a
Sucrose Non Fermenting 2 (SNF2)-type DNA-dependent
ATPase domain that functions to remodel chromatin[16–18].
The functional full-length protein has been shown to play an
important role in chromosomal integrity, maintaining
organization and sister chromatid cohesion during cell
division[19].
While there have been various developmental studies that
show severe effects of tissue-specific Atrx deficiency[20–23]
cartilage-specific inactivation of the Atrx gene in mice does not
result in major phenotypes[24]. On the other hand, loss of Atrx
in the forebrain and pituitary of mice leads to features of
aging[25], prompting us to ask whether Atrx is important in
aging skeletal elements and joints. Since ATRX is highly
expressed in chondrocytes[24], it could be a potential
epigenetic regulator of specific genes involved in healthy
cartilage maintenance and its loss may lead to diseases such
as osteoarthritis. This study examined the role of ATRX in three
models of Atrx deficiency and assessed the onset and
progression of osteoarthritis using Osteoarthritis Research
Society International (OARSI) histopathology guidelines and
molecular markers of OA.

were as follows: 95°C for 3 min (95°C for 30 s, 55°C for 45 s,
and 72°C for 1 min) × 36, 72°C for 10 min for Cre , 95°C for 3
min (95°C for 30 s, 55°C for 1 min, and 72°C for 5 min) × 36,
72°C for 10 min for Atrx..

Histological staining of bone and joint sections

Materials and Methods

Limbs were dissected from Atrx-depleted mice upon sacrifice
and processed for histological analyses by Picrosirius red,
safranin-O
and
immunohistochemical
staining
as
described[31–33]. For histological analyses, specimens were
fixed in 4% paraformaldehyde, decalcified with 5% EDTA,
paraffin
embedded
and
sectioned
at
5μm.
For
immunohistochemistry, samples were examined in dewaxed
paraffin–embedded sections. Following dehydration, sections
were blocked in hydrogen peroxide followed by 5% goat serum,
and incubated with a polyclonal rabbit antibodies to MMP13
(Santa Cruz), aggrecan fragments (MMP Cleaved, N-terminus
FFGVG neoepitope, Millipore), Atrx (Prestige Antibodies,
Sigma-Aldrich) or type II collagen (Santa Cruz) according to
manufacturer's instructions. Following overnight incubation at
4°C sections were incubated with HRP–conjugated secondary
goat antibody against rabbit IgG and detected by staining with
DAB (Dako). To quantify trabecular area, sections were stained
for one hour in 0.1% Picrosirius Red. Using imageJ software,
an area of interest (AOI) was set from the chondro-osseous
junction to 200μm below the growth plate in the trabecular
bone area of the mineralized zone, as described previously[25].

Animals

Histological end-stage analysis

The cartilage-specific Atrx depleted Atrxfl/yCol2a1cre+ (AtrxCol2)
mice were generated as described previously[24]. Both wildtype and AtrxCol2 mice were maintained until the age of two
years. Bone-specific Atrx depleted mice were generated using
an osteoblast-specific cre mouse[26] to generate Atrxfl/yCol1a1cre+
(AtrxCol1) mice. Forelimb specific deletion of Atrx was generated
as described previously using the forelimb-specific Prx1-cre
[27,28]. Since Atrx is X-linked, male mice resulting from these
crosses carry one copy of the Atrx gene containing the loxP
sites and Cre-positive males were conditionally Atrx-null. All
animals in this study were male mice from the first generation
of this cross between B57Bl/6 and 129/SV backgrounds. This
study was conducted in strict accordance with Canadian
Council on Animal Care (CCAC) guidelines for ethical use and
care of animals. All experiments involving animals were
approved by the Council on Animal Care at the University of
Western Ontario (Permit number: 2007-045-10).
PCR genotyping from ear tissue for Cre and Atrx as
described previously[24]. Atrxfloxed and Cre alleles were
confirmed as previously described [29,30].. A 1.5 kb fragment
containing the neo cassette within the Atrx floxed allele was
identified
with
one
set
of
primers
(5′GATCGGCCATTGAACAAGAT-3′ and 5′-ATA GGT CGG CGG
TTC AT-3′) whereas the wild-type allele was detected with
another set (5′-CCC GAG TAT CTG GAA GAC AG-3′and 5′ATA GGT CGG CGG TTC AT-3′). Primers (5′-CCT GGA AAA
TGC TTC TGT CC-3′) and (5′-CAG GGT GTT ATA AAC AAT
CCC-3′) were used to amplify a common 300 base pair
fragment for all three versions of the cre gene. PCR conditions
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Sections from a minimum of three independent litters were
stained with Safranin-O and fast green, and graded according
to the Osteoarthritis Research Society International (OARSI)
scoring system[34]. OA scores were assigned by two blinded
observers and total score was calculated by averaging the
grade and stage values for each slide (a minimum score of 0
represents no OA degradation and a score of 6 represents the
maximum degree of OA). Maximal OARSI grade was
determined for each joint based on the surface displaying the
highest OARSI score in each section.

Skeletal stains and measurements
Live mice were weighed at P0 and P21. Animals were
skinned and eviscerated, fixed overnight in 95% ethanol
followed by overnight fixation in acetone for Alizarin Red/Alcian
Blue staining. Whole skeletons were stained for 7–10 days
(0.05% Alizarin Red, 0.015% Alcian Blue, 5% acetic acid in
70% ethanol)[31]. Skeletons were cleared in 2% w/w KOH.
Bones were imaged on an Olympus SP-57OUZ camera. Limb
bones and skulls from at least three independent littermate
pairs were measured using a dissecting microscope with a
ruler.

Microcomputed tomography
Male AtrxCol1 and control littermate mice were sacrificed at
weaning (21 days of age), skinned and eviscerated, followed
by fixation in formalin. Whole bodies were imaged using a
scanner (eXplore Locus MicroCT; GE Healthcare) at 120 kV
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cartilage appeared relatively healthy with only minor
degeneration. Maximal OARSI score of the knee joint was not
different in controls compared to AtrxCol2 mice. Control mice had
a maximal knee score 1.70 and mutant mice had a maximal
score of 1.53 (p= 0.89) (Figure 1A). AtrxCol2 mice did not show a
significant increase in fibrillation and fissuring of the articular
surfaces. Absence of ATRX protein in articular cartilage was
confirmed by immunohistochemistry using a rabbit anti-ATRX
antibody (Prestige Antibodies, Sigma-Aldrich) on sections from
knee (Figure 1B) and elbow joints (not shown).

and 20 mA, with a 0.154 mm3 voxel resolution with a total of
900 slices per scan. Bone mineral density (BMD), cortical
thickness and trabecular numbers were calculated using the
Microview 3D visualization and analysis software (MicroView,
Version 2.1.2, GE Healthcare Biosciences)[35].

Osteoblast isolation and differentiation
Calvarial cells were isolated from 8-10 day old ATRXCol1 mice
using sequential collagenase digestion, as previously
described[36,37]. Briefly, calvaria from control and mutant mice
were dissected, scraped clean of mesenchyme by micro
dissection, and digested through three changes of collagenase.
Pooled cells from the latter two changes of collagenase were
plated on six-well plates at a density of 1.5 × 104 cells/cm2 in
culture medium. After three days, cells were transferred to high
density micromass cultures in 24-well plates, with each well
containing 5 × 104 cells in a 150-μl drop of culture medium.
After 12 hours, culture medium was added to the micromass
cultures. Culture media was supplemented with 50 μg/ml
ascorbic acid and 2 mM β-glycerophosphate, and cultures were
maintained for up to 4 weeks.

MMP13, Aggrecan fragment and Collagen 2 levels are
normal in AtrxCol2 mice
Several molecular changes have been associated with OA.
MMP13 (matrix metalloproteinase 13) plays a catabolic role in
the progression of cartilage degeneration and cleaves
collagens, gelatin, and aggrecan[3,38]. Aggrecan is an
extracellular matrix protein and its degradation into fragments
is accelerated in OA[39]. Finally, type II collagen is cleaved by
a number of MMPs including MMP13. In arthritic joints, loss of
the collagen matrix is accelerated, leading to erosion of the
articular surface[34].
Using immunohistochemistry, we detected no visible
difference in Mmp13 levels in tibia articular cartilage between
control and mutant mice. The level of Mmp13 in the cartilage
was quantified as a percentage of Mmp13 positive cells to total
cells in 1000 pixel wide sections of articular cartilage. Statistical
analysis confirmed that there was no significant difference in
Mmp13 levels between mutants and control littermates (35.7%
vs. 39.3% respectively, p= 0.451) (Figure S1A,B). Tibial
aggrecan fragment levels was also not altered between control
and AtrxCol2 mice as revealed by IHC analysis. Control and
knockout mice were not significantly different in the percentage
of aggrecan fragment-positive cells versus total cells in articular
cartilage(34.02% vs. 22.87%, p= 0.074) (Figure S1C, D). Upon
immunostaining for type II collagen, we observed that the mean
thickness of the type II collagen -positive zone of the articular
cartilage was not significantly different when comparing the
tibiae of control and mutant mice (87.993 μm vs. 90.065 μm, p=
0.837). There was also no significant difference in the
thickness of type II collagen-positive articular cartilage between
the femurs of controls and mutant mice (82.080 μm vs. 81.142
μm, p= 0.923)(Figure S1E,F).

Analyses of alkaline phosphatase activity and mineral
deposition
Calvarial micromass cultures were fixed in 4% PFA overnight
at 4°C. Alkaline phosphatase activity was assayed using a
mixture of 1.25 mM Fast Red B salt in 0.1 M Tris-HCl, pH 8,
and 0.25 mM naphthol AS-MX phosphate, protected from light
for one hour. Mineralised nodules were visualised following
ALP staining using 2.5% silver nitrate solution for 1 h with
exposure to light.

Results
Skeletal phenotypes of adult AtrxCol2 mice
To determine if Atrx played a direct role in skeletal
development, mice with cartilage-specific inactivation of Atrx
were generated utilizing the Cre-LoxP system. Female mice
previously engineered with LoxP sites flanking exon 18
of Atrx [20]. were crossed with male mice expressing Cre
recombinase under the control of the mouse collagen II
(Col2a1) promoter[30]. Cre-positive male offspring lacked Atrx
in the developing cartilage but developed normally with only
minor defects in skeletogenesis[24]. AtrxCol2 mice were born at
normal Mendelian ratios and did not demonstrate defects in
skeletal size or growth plate morphology at birth or
weaning[24].
To examine if embryonic depletion of Atrx in the developing
cartilage contributes to reduced cartilage integrity later in life,
two-year old AtrxCol2 mice were examined for signs of
osteoarthritis and other skeletal defects. No significant weight
difference was observed between control and mutant mice at
two years of age (Ctrl: 36.57 ± 6.38 grams, AtrxCol2: 31.56 ±
8.51 grams). Sections of knee joints from control and mutant
AtrxCol2 mice were assessed for osteoarthritis using the OARSI
histopathology guidelines[34] on tissue sections stained for
cartilage proteoglycan with safranin-O. In both genotypes,
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Loss of ATRX in during forelimb development does not
lead to forelimb osteoarthritis
AtrxPrx1 mice were previously characterised and display
brachydactyly and abnormal gait[27]. We now examined the
joints to determine if structural variations in the limb might alter
kinematics and thus lead to joint disease. Forelimb and
hindlimb joints from AtrxPrx1 mice were examined for
osteoarthritis at two years of age (Figure 2). Although the
forelimbs of AtrxPrx1 are derived from ATRX-depleted
mesenchyme, no difference was seen in the articular cartilage
of the forelimb joint (Figure 2A). Control animals had a mean
score of 1.32 and mutants has a mean score of 1.50 (p= 0.82).
Similar to other models of ATRX loss in the skeleton, AtrxPrx1
mice do not demonstrate knee osteoarthritis, with a maximal
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Figure 1. Characterisation of joint morphology in two year-old AtrxCol2 mice. A) Minor fibrillation and fissuring of the tibial and
femoral articular surfaces was observed in both genotypes, demonstrating mild osteoarthritis in both genotypes. OARSI scoring
confirmed the absence of significant differences between genotypes. Scale bar = 96 µm. B) Immunohistological staining of articular
cartilage, demonstrating that ATRX protein is present in normal aged articular cartilage, but absent from the nuclei of mutant
chondrocytes. Scale bar = 48 µm.
doi: 10.1371/journal.pone.0085526.g001

OA score of 2.18 in mutant knees and 1.78 in control
littermates (p=0.69) (Figure 2B). Loss of ATRX in articular
cartilage derived from ATRX-deficient forelimb mesenchyme
was confirmed by staining with IHC (Figure 2C).

was confirmed by IHC staining with rabbit anti-ATRX (Prestige
Antibodies, Sigma Aldrich) in cortical and subchondral bones
(Figure 3F).

AtrxCol1 mice have normal mineralisation and circulating
IGF-1

Atrx
mice exhibit reduced growth without growth
plate abnormalities
Col1

Micro-computed tomography (Micro-CT) analysis was
performed at weaning and showed no changes in
endochondral or intramembranous ossifications. Tibias
appeared to have no gross morphological differences (Figure
4A) and trabecular bone mineral density (BMD) was
unchanged between genotypes (Figure 4B) (N = 3, p >0.05).
Trabecular number was also not significantly changed when
analysed by Micro-CT (Figure 4C).
IGF-1 promotes longitudinal bone growth and reduced IGF-1
is associated with limb shortening[40]. To determine a possible
endocrine component to the dwarfism in AtrxCol1 mice, levels of
circulating IGF-1 were measured by ELISA. This analysis
revealed no significant difference in IGF-1 levels between
control and mutant mice (207.433 ± 35.4 ng/ml vs. KO:
252.010 ± 56.8 ng/ml, respectively p =0.17).
To further investigate the role of ATRX in osteogenesis, we
compared mineralisation in calvarial cells from control and
AtrxCol1 mice. Unlike long bones, which form through a cartilage
intermediate, calvarial bone forms by intramembranous
ossification and does not contain cartilage. Examination of
skeletal preparations from 21-day-old mutant mice revealed no

To examine the role of ATRX in bone-forming osteoblasts,
the Col1a1-Cre driver line was utilized[26]. AtrxCol1 mice were
born at normal Mendelian ratios, showing that loss of Atrx in
the osteoblast does not lead to embryonic or perinatal lethality
(Figure 3A). In the neonatal period AtrxCol1 mice exhibited
reduced growth compared to their control littermates, and at
weaning they were smaller and had shorter limbs (Figure 3B).
Bone length measurements of the appendicular skeleton
showed that the forelimb long bones of AtrxCol1 mice (ulna,
radius, humerus) are significantly shorter than those of
controls, while the shortening of femur and tibia was not
statistically significant (Figure 3C). Histological analysis of long
bones by picrosirius red staining did not show any changes in
growth plate morphology or trabecular density between
genotypes (Figure 3D, and Figures S2,S3). Additionally,
establishment of the secondary ossification center was not
delayed in long bones of 10 day old mutant mice, as
determined by safranin-O staining (not shown). At one year of
age, AtrxCol1 mice remained smaller than control littermates and
did not catch up in weight (Figure 3E). Loss of ATRX in bone
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Figure 2. Characterisation of joint osteoarthritis in AtrxPrx1 mice. A) Mild fibrillation and fissuring of the articular surfaces was
observed in elbows of control or mutant mice, and no difference was seen between genotypes. Scale bar = 96 µm. B) Integrity of
the knee was similar in control and mutant mice. C) Immunohistological staining of articular cartilage from the elbows of mice,
demonstrating that ATRX protein is present in normal aged articular cartilage, but absent from the nuclei of chondrocytes derived
from ATRX deficient forelimb mesenchyme. Scale bar = 48 µm.
doi: 10.1371/journal.pone.0085526.g002

Loss of ATRX in bone does not lead to osteoarthritis

differences in calvarial structure or suture formation (Figure
5A). Mutant skulls appeared smaller than those of littermates,
but were not significantly smaller by length (p=0.15) or width
(p=0.14) (Figure 5B). To analyze mineralisation by ATRXdepleted osteoblasts, calvarial cells in 3D micromass culture
were examined. Osteogenic media was supplemented with βglycerophosphate and ascorbic acid for a four-week time
course. The extent of differentiation and formation of
mineralised nodules was assayed by alkaline phosphatase and
von Kossa staining. While cultures increased mineralization
over the time course as expected, no difference was observed
between genotypes at any time over the four-week culture
(Figure 5C).

PLOS ONE | www.plosone.org

To determine if loss of ATRX in osteoblasts would lead to
joint damage and osteoarthritis, joints of AtrxCol1 mice were
examined for osteoarthritis at one year of age (Figure 6).
AtrxCol1 mice expressed the same amount of ATRX in articular
cartilage as control littermates, as expected with this Cre driver
line (data not shown). Maximal OARSI scores of osteoarthritis
in the elbows of AtrxCol1 mice were low in both genotypes;
control animals had a mean score of 0.63 and mutants has a
mean score of 0.67 (p= 0.92) (Figure 6A). Knee osteoarthritis
scores were slightly higher, with control animals having an
averaged maximal score of 1.46 for any quadrant of frontal
knee sections and ATRX-deficient animals having a score of
0.67 (Figure 6B). These values were not significantly different
(p=0.20).
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Figure 3. AtrxCol1 mice exhibit reduced growth without growth plate abnormalities. . A) Mice lacking Atrx in osteoblasts are
born at normal Mendelian ratios. B) Overall skeletal morphology of AtrxCol1 examined by alican blue/alizarin red stain reveals
reduced overall size and shortened limbs. C) Longitudinal measurements of the bones of the axial skeleton demonstrate that all
bones in the mutant are shortened, and forelimb bones show significant shortening compared to controls N=5 (* p<0.05). D)
Mineralised trabecular bone area below the growth plate at weaning is not different between genotypes upon visualization of
sections stained with picrosirius red staining. Scale bar = 192 µm. E) AtrxCol1 mice are slightly smaller by body weight compared to
littermates at birth, weaning and adulthood. F) IHC staining for Atrx protein demonstrates reduced Atrx in AtrxCol1 cortical and
subchondral bone. Scale bar = 48 µm.
doi: 10.1371/journal.pone.0085526.g003

Discussion

disease progression. Injury can also be underlying cause of
OA, and further studies challenging the animals with joint
trauma could be considered in the future.
In the present study, we found that loss of Atrx in osteoblasts
causes mild but significant shortening of the limbs. Given the
similar, but more severe, dwarfism observed when Atrx is
deleted in the developing forebrain and anterior pituitary [25], it
is possible that this dwarfism is due to an indirect effect,
because of unspecific Cre expression. The possibility of an
indirect effect is supported by the fact that ex-vivo cultures of
ATRX-null osteoblasts mineralise normally. Evidence suggests
that the Col1a1-cre used in this study is capable of some LoxP
recombination in the brain, so there remains a possibility that
part of the dwarfism phenotype may be due to leaky Atrx
recombination in the brain[41]. On the other hand, normal
circulating IGF1 levels suggest that reduced skeletal growth is
due to disruption of a bone-intrinsic role of Atrx.
In previous reports, a direct or indirect role for ATRX in the
development of the skeleton has been characterised[24,25,27].
Alterations in the expression of other chromatin-remodelling
proteins
in
the
skeleton
can
lead
to
severe
malformations[42,43]. For example, dominant negative
mutations in the SWI/SNF subunit BRG1 reduce levels of the
transcription factor RUNX2, an important regulator of
osteogenesis[43]. However, no equivalent changes were
observed in the expression of Runx2 or other osteogenic genes
in Atrx-null calvaria (data not shown). Osteoblast precursors
isolated from AtrxCol1 mice matured in high density micromass

Loss-of-function mutations in the human ATRX gene are
associated with skeletal defects and high incidence of
dwarfism. Mouse models of ATR-X syndrome have similar
phenotypes, and demonstrate premature aging[25,27]. We
report that aged mice lacking Atrx in skeletal tissues (AtrxCol2,
AtrxCol1, and AtrxPrx1) show very limited skeletal defects, with no
associated increase in osteoarthritis.
AtrxCol2 mice exhibit minimal skeletal defects during
development[24], so it was not completely surprising that
cartilage integrity was maintained during normal aging. Adult
AtrxCol2 mice displayed minor fibrillation and loss of
proteoglycan in the articular cartilage, but at equal levels as
aged-matched control littermates. Thus, given the relative
stability of Atrx-null articular cartilage, Atrx does not appear to
be required for structural maintenance of articular cartilage.
No phenotype was observed in the AtrxPrx1 mouse, despite
biomechanical differences observed between genotypes
leading to stride alterations[27]. AtrxPrx1 mice have shortened
digits and reduced function, but only demonstrate Atrx loss in
the forelimb and not the hindlimb. Therefore, it was expected
that no differences would be observed in the hindlimb articular
cartilage, as the hindlimbs of these animals can be considered
wild-type due to the expression of the forelimb cre during
development[28].
While this study is reflective of the majority of OA cases
related to aging, it does not consider the role of injury in
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when examined histologically, as well as by Micro-CT analysis.
Therefore, we conclude that loss of Atrx in osteoblasts does
not impede their ability to mineralise tissue.
When Atrx is lost in the developing limb bud, DNA damage is
observed as an accumulation of y-H2AX-positive nuclei in
forelimb cells[27]. This single focus co-localises with DNA
damage response factor 53BP1 at the nuclear lamina, and
forelimbs lacking Atrx have higher incidence of TUNEL
staining[27]. However, loss of Atrx in this model caused only a
slight increase in apoptotic cells compared to other tissues
such
as
brain,
trophoblast,
muscle
and
Sertoli
cells[20,21,23,44]. Thus, our findings suggest that the
protective effect of ATRX against DNA damage and replicative
stress is tissue-specific, and that skeletal tissues are more
resistant to the effects of Atrx loss.
In conclusion, ATRX deletion in various skeletal lineages
confers only mild, tissue-specific defects and does not fully
recapitulate the skeletal phenotypes of ATR-X syndrome.
Furthermore, there is no increased incidence of joint
osteoarthritis and no difference in the progression of skeletal
pathologies in adulthood. Although ATRX mutations are
associated with skeletal defects in humans, the underlying
cause is likely indirect due to reduced function of ATRX in other
tissues[25]. In conclusion, ATRX is important in the developing
skeleton prior to chondrocyte differentiation and during
mineralisation, but is not important for maintenance of adult
skeletal tissues.

Figure 4. AtrxCol1 mice have normal mineralisation. A)
Representative tibias from weaned AtrxCol1 showing that there
was no gross morphological differences in the long bones
between genotypes. B) No difference in bone mineral density
(p = 0.90) was observed between AtrxCol1 mice and controls.
Error Bars - SD, N=3 C) Trabecular number was unchanged
between AtrxCol1 mice compared with controls (p = 0.46). MicroCT data were obtained from hind legs using MicroView 3D
software Error Bars - SD, N =3.
doi: 10.1371/journal.pone.0085526.g004

culture and formed mineral at the same rate as cells from
control littermates. Finally, trabecular density was unaffected
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Figure 5. Ossification is not impeded or delayed by Atrx depletion in osteoblasts. . A) Ossification of the skull is normal in
AtrxCol1 mice, and no changes are seen in suture formation. B) Skull length and width are not significantly affected in AtrxCol1 mice
compared to controls. N=5, Error bars - SD C) Mineralisation of high-density osteoblast cultures. Control and Atrx-null osteoblasts
show mineralised nodules (black) after two weeks in osteogenic media, and mineralise at similar rates at three and four weeks.
Representative images from five trials.
doi: 10.1371/journal.pone.0085526.g005
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Figure 6. Characterisation of joint osteoarthritis in AtrxCol1 mice. . A) Fibrillation or fissuring of the articular surfaces was not
observed in elbows of control or mutant mice, demonstrating very mild OA in both genotypes. Scale bar = 96 µm. B) Joint integrity
of the medial surface of the knee was similar in control and mutant mice. N = 4, Error bars = SD.
doi: 10.1371/journal.pone.0085526.g006
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Supporting Information

type II collagen-positive zone in controls and knockout mice
was 82.080 ± 8.820 μm vs. 81.142 ± 5.084 μm (n= 8). Neither
the tibiae nor femurs of control and knockout mice showed any
significant differences (p> 0.05).
(TIF)

Figure S1. Figure S1A. MMP13 expression is similar in the
articular cartilage of AtrxCol2 mice compared to controls.
Representational immunohistochemical stains of articular
cartilage in Atrx mutant and control mice performed on paraffin
sections. Scale bar = 200 μm. Figure S1B. MMP13 expression
was not significantly changed in AtrxCol2 mice. Analysis was
performed by counting the percentage of MMP13-positive cells
in paraffin sections using representational subsets of tibial
articular cartilage. The average percentage of positive cells per
articular surface was 35.7 ± 0.67% for controls and 39.3 ±
14.2% positive cells for mutants(n= 8). Control and knockout
sections were not significantly different (p> 0.05). Figure S1C.
Tibial aggrecan fragmentation is unchanged in AtrxCol2 mice.
Representational stains for aggrecan fragments in control and
knockout mice on 5μm paraffin sections. Scale bar = 200μm.
Figure S1D. Tibial aggrecan fragmentation in unchanged in
AtrxCol2 mice. The average number of aggrecan fragmentpositive cells in controls was 34.02 ± 5.92% (Mean ± SEM) (n=
5). The mean percentage of positive cells in knockouts was
22.8 ± 10.65% (n= 8). Mean percentages of aggrecan
fragment-positive cells between controls and knockout tibiae
were not significantly different (p> 0.05). Figure S1E. The type
II collagen -positive zone in articular cartilage of knees of
control and AtrxCol2 mice. Immunohistochemistry stains on
paraffin knee sections for collagen 2. Scale bar = 200μm.
Figure S1F. The thickness of the type II collagen-positive zone
in the articular cartilage of the tibia and femur is not different in
AtrxCol2 mice. Three measurements of the type II collagen positive zone in the tibia and femur were taken. The average
tibial thickness of the type II collagen positive zone in controls
vs. knockout mice was 87.993 ± 8.827 μm vs. 90.065 ± 5.529
μm (Mean ± SEM) (n= 5). The average femoral thickness of the

Figure S2. Growth plate measurements in AtrxCol1 mice. No
significant difference was seen in the length of the resting,
proliferating or hypertrophic zones in long bones in AtrxCol1 or
Control littermates at weaning (N = 3 littermate pairs; two-tailed
T-test). Error bars - SD.
(TIF)
Figure S3. Trabecular area quantification in AtrxCol1 mice.
Quantification of the area of mineralised trabecular area shows
that mineralisation is unaffected in AtrxCol1 mice. No difference
in trabecular area below the growth plates in the tibia, femur or
humerus between AtrxCol1 mice and controls.
(TIF)
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